U.S., Dec. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07297693) titled 'A Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy Volunteers' on Dec. 09.
Brief Summary: The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HIP2503 and HCP1306 in healthy volunteers.
Study Start Date: Dec. 19
Study Type: INTERVENTIONAL
Condition:
Healthy
Intervention:
DRUG: HIP2503
Take 1 orally disintegrating tablet once per period
DRUG: HCP1306
Take 1 tablet once per period
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Hanmi Pharmaceutical Company Limited
Published by HT Digital Content Services with permission from Health Daily Dig...